In the experimental studies with animal models, down-regulation of FasL expression in carcinoma significantly reduces tumor development in syngeneic immunocompetent mice [72], while persistent expression of Fas enhances tumor growth along with an increase in lymphocyte apoptosis [73,74], and is acquired for survival from active specific immunotherapy [75]. The gene discussed is FASLG; the disease is carcinoma.